merged_alzheimers-treatment-kisunla-donanemab.txt
<other>Reviewing the article, the responses below are based solely on the text provided.</other>
<question_number>1</question_number>
<answer>Significant safety risks such as brain swelling and bleeding.</answer>
<question_number>2</question_number>
<answer>It may discourage patients from participating in other, potentially more effective, clinical trials.</answer>
<question_number>3</question_number>
<answer>No observed correlation between amyloid plaque removal and individual clinical response.</answer>
<question_number>4</question_number>
<answer>It may heighten safety concerns, making Kisunla appear riskier.</answer>
<question_number>5</question_number>
<answer>Because patients can discontinue treatment after clearing amyloid plaques, reducing ongoing costs and inconvenience.</answer>
<question_number>6</question_number>
<answer>It may discourage patients from joining other clinical trials.</answer>
<question_number>7</question_number>
<answer>Patients can stop dosing once amyloid plaques are cleared, reducing treatment frequency and inconvenience.</answer>
<question_number>8</question_number>
<answer>Amyloid.</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius.</answer>
<question_number>10</question_number>
<answer>That patients with intermediate tau levels experienced slower cognitive decline.</answer>